Description
LL-37 – Technical Biochemical Mechanism Profile
(Cationic Antimicrobial Host-Defense Peptide; Cathelicidin-Derived – Research Use Only)
LL-37 is a 37-amino-acid cationic α-helical peptide derived from the C-terminal cleavage of the human cathelicidin precursor hCAP-18.
In vitro models demonstrate that LL-37 exerts broad-spectrum antimicrobial, immunomodulatory, and wound-repair signaling functions through membrane disruption, TLR signaling modulation, and EGFR/MAPK pathway activation, resulting in differential gene transcription across immune and epithelial systems.
✅ 1. Molecular and Cellular Targets
LL-37 interacts with:
-
Bacterial and viral membranes (negatively charged phospholipids → pore formation)
-
TLR2, TLR4, TLR9 (pattern-recognition receptors)
-
P2X7 purinergic receptor
-
EGFR (epidermal growth factor receptor)
-
FPR2 (formyl peptide receptor-2) on immune and epithelial cells
These interactions trigger downstream cytokine, chemokine, and repair-related signaling cascades.
✅ 2. Core Biochemical Mechanisms
A. Membrane Disruption (Pathogen-Directed)
-
Electrostatic binding to anionic phospholipids
-
α-helix insertion into lipid bilayers
-
Pore formation → membrane lysis
-
Loss of ionic gradient and metabolic collapse in microbes
B. Immunomodulatory Signaling (Host-Directed)
TLR Modulation
LL-37 directly binds:
-
TLR2/TLR4 ligands → altered NF-κB output
-
CpG-DNA → TLR9 signaling
-
Inhibits LPS–TLR4 inflammatory amplification
NF-κB Downstream Targets Affected:
-
↓ TNFA, IL1B, IL6, COX-2 (PTGS2)
-
↑ IL10, TGFB1
P2X7 Pathway
Binding to P2X7 receptors promotes:
-
↑ Ca²⁺ influx
-
NLRP3 inflammasome activation in some immune cell types
-
IL-1β maturation and release
C. EGFR / MAPK / ERK Signaling (Tissue Models)
LL-37 triggers transactivation of EGFR, producing:
-
↑ ERK1/2 phosphorylation
-
↑ MAPK activation
-
↑ CREB-regulated transcription
Genes commonly monitored:
-
VEGFA (angiogenesis)
-
EGF, FGF2
-
MMP9, MMP2 (matrix remodeling)
-
COL1A1, FN1 (extracellular matrix organization)
D. Chemotactic Signaling via FPR2
LL-37 functions as a ligand for FPR2/ALX:
-
Activation of G-protein–dependent Ca²⁺ flux
-
Neutrophil and macrophage chemotaxis
-
Recruitment of immune cells to injury or infection sites in research models
✅ 3. Enzymes & Second Messengers
| Component | Role in LL-37 Activity |
|---|---|
| NF-κB | Inflammatory gene regulation |
| MAPK/ERK | Cell migration, proliferation gene activation |
| MMP-2 / MMP-9 | ECM remodeling |
| Caspase-1 (via NLRP3) | IL-1β maturation |
| Ca²⁺ | Chemotaxis, gene transcription |
| PLC → IP₃ / DAG | GPCR signaling cascade |
✅ 4. Gene Targets Frequently Measured in Research
| Functional Category | Representative Genes |
|---|---|
| Angiogenesis | VEGFA, FGF2, ANGPT1 |
| Inflammation Modulation | IL10, TGFB1, ↓ TNFA, IL1B |
| Matrix Remodeling | MMP2, MMP9, COL1A1, FN1 |
| Immune Recruitment | CXCL8 (IL-8), CCL2 |
| Antimicrobial Peptides | DEFB4A (hBD-2) induction |
✅ 5. Antimicrobial Actions
-
Cationic amphipathic helix binds microbial envelopes
-
Inserts into membrane → torroidal pore formation
-
Leads to ion leakage, ATP loss, membrane rupture
Targets include:
-
Gram-positive & Gram-negative bacteria
-
Fungi
-
Enveloped viruses (via membrane interaction)
✅ Mechanistic Summary
-
Endogenous human cathelicidin-derived peptide
-
Broad GPCR, TLR, and EGFR signaling effects
-
Activates MAPK/ERK, NF-κB modulation, P2X7–Ca²⁺ influx, and MMP/VEGF gene pathways
-
Potent membrane-disruptive antimicrobial activity in vitro
✅ Research-Only Classification
LL-37 is supplied strictly for controlled in-vitro laboratory research.
Not approved for human or animal administration, ingestion, injection, or therapeutic application.
If you’d like, I can also provide:
